Abstract
Drug treatment poses a therapeutic challenge in cystic fibrosis (CF) because the disposition of a number of drugs is altered in CF. Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have previously been reported in CF patients. The objective of the current study was to investigate if the CF-knockout mouse model (cftrm1UNC) shows altered pharmacokinetics similar to those seen in CF patients using the 2 model compounds APAP and ICG. Clearance (CL/F) of APAP and renal (CLR) and formation (CLf) clearance of acetaminophen glucuronide (AG) and acetaminophen sulfate (AS) were determined in CF-knockout mice following administration of APAP (50 mg/kg, intraperitoneal). CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was significantly different between groups. CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching statistical significance. No significant differences were noted in either ClR or CLf of AG and AS in female CF mice. Plasma concentrations of ICG (10 mg/kg, intravenous) were determined over 0 to 15 minutes. Homozygous females showed a higher apparent volume of distribution (96 mL/kg) relative to heterozygous females (72 mL/kg). Similar to CF patients, a trend toward a lower Cmax was noted in homozygous male and female mice. However, contrary to human data, no significant differences in CL of ICG were noted. These results suggest that the CF-knockout mice have potential as a model for studying altered drug disposition in CF patients.
Similar content being viewed by others
References
Welsh MJ, Smith AE. Cystic fibrosis. Scientific American. 1995;273:52–59.
Kearns GL, Mallory GB, Crom WR, Evans WE. Enhanced hepatic drug clearance in patients with cystic fibrosis. Pediatr Pharmacol Ther. 1990;117:972–979.
Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother. 1993;27:74–79.
Kearns GL, Crom WR, Karlson KH, Mallory GB, Evans WE. Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmcol Ther. 1996;59:529–540.
Hutabarat RM, Unadkat JD, Kushmerick P, Aitken ML, Slattery JT, Smith A. Disposition of drugs in cystic fibrosis. III. Acetaminophen. Clin Pharmacol Ther. 1991;50:695–701.
Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH. The relationship of chronic mucin secretion to airway disease in normal and cftr-deficient mice. Am J Resp Cell Mol Biol. 1998;19:853–866.
Snouwaert JN, Brigman KK, Latour et al. An animal model for cystic fibrosis made by gene targeting. Science. 1992;257:1083–1088.
Miller DA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
Wang LH, Rudolph AM, Benet LZ. Pharmacokinetic studies of the disposition of acetaminophen in the sheep maternal-placental-fetal unit. J Pharmacol Exp Ther. 1986;238:198–205.
Heintz R, Svensson CK, Stoeckel K, Powers GJ, Lalka D. Indocyanine green: pharmacokinetics in the rabbit and relevant studies of its stability and purity. J Pharm Sci. 1986;75:398–402.
Ott P, Keiding S, Bass L. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis. Hepatology. 1993;6:1504–1515.
Falls JG, Blake BL, Cao Y, Levi PE, Hodgson, E. Gender differences in hepatic expression of flavin-containing monooxygenase isoforms (FMO1, FMO3, and FM05) in mice. J Biochem Tox. 1995;10:171–177.
Rao UN, Aravindakshan M, Satyanarayan V, Chauhan PS. Genotype-and gender-dependent hepatic alcohol dehydrogenase (ADH) activity in developing mice. http://www.ncbi.nlm.nih.gov/htbin-post/PubMed/wgetcit?journal=Alcohol&volume=14&page=527&display=abstract&format=htmlAlcohol. 1997;14:527–531.
Kane RE, Tector J, Brems JJ, Li AP, Kaminski DL. Sulfation and glucuronidation of acetaminophen by cultured hepatocytes replicating in vivo metabolism. ASAIO Transactions. 1990;36:607–610.
Surh YJ, Liem A, Miller EC, Miller JA. Age-and sex-related differences in activation of the carcinogen 7-hydroxymethyl-12-methylbenz[a]anthracene to an electrophilic sulfuric acid ester metabolite in rats. Biochem Pharmacol. 1991;41:213–221.
Nakagomi M, Suzuki E, Kitashima M, et al. Sex difference in the metabolism of pirmenol in rats. Biol Pharm Bull. 1997;20:1279–1284.
Rao UN, Aravindakshan M, Satyanarayan V, Chauhan PS. Genotype-and gender-dependent hepatic alcohol dehydrogenase (ADH) activity in developing mice. http://www.ncbi.nlm.nih.gov/htbin-post/PubMed/wgetcit?journal=Alcohol&volume=14&page=527&display=abstract&format=htmlAlcohol. 1997;14:527–531.
Urakami Y, Nakamura N, Takahasi K, et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Letters. 1999;461:339–342.
Bradley G, Georges E, Ling V. Sex-dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol. 1990;145:398–408.
Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev. 1999;79:193–214.
McPhail ME, Knowles RG, Salter M, Dawson J, Burchell B, Pogson CI. Uptake of acetaminophen (Paracetamol) by isolated rat liver cells. Biochem Pharmacol. 1993;45:1599–1604.
Miyazaki K, Takemoto C, Satoh T, Ueno K, Igarashi T, Kitagawa H. Toxicity and biotransformation of acetaminophen in rat hepatocytes (I). Uptake and release. Res Comm Chem Pathol Pharmacol. 1983;39:77–86.
Slattery JT, McRone TI, Reynolds R, Kalhorn TF, Kharasch ED, Eddy C. Lack of effect of cimetidine on acetaminophen disposition in humans. Clin Pharmacol. 1989;46:591–597.
Slattery JT, Wilson JM, Kalhorn TF, Nelson SD. Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin Pharmacol Ther. 1987;41:413–418.
Hjelle JJ. Hepatic UDP-glucuronic acid regulation during acetaminophen biotransformation in rats. J Pharmacol Ther. 1986;237:750–756.
Radi R, Tan S, Prodanov E, Evans RA, Parks DA. Inhibition of xanthine oxidase by uric acid and its influence on superoxide radical production. Biochimica et Biophysica Acta. 1992;1122:178–182.
Milne ML, Baran DT. End product inhibition of hepatic 25-hydroxyvitamin D production in the rat: apecificity and kinetics. Arch Biochem Biophys 1985;242:488–492.
Wang LH, Rudolph AM, Benet LZ. Comparative study of acetaminophen disposition in sheep at three developmental stages, the fetal, neonatal, and adult periods. Devel Pharmacol Ther. 1990;14:161–179.
Trezise AEO, Ratcliff R, Hawkins TE, et al. Co-ordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice. Hum Mol Genetics. 1997;6:527–537.
Trezise AEO, Romano PR, Gill DR, et al. The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J. 1992;11:4291–4303.
Johannesson M, Nordqvist AS, Bogdanovic N, Hjelte L, Schalling M. Polymorphic expression of multidrug resistance mRNA in lung parenchyma of nonpregnant and pregnant rats. A comparison to cystic fibrosis mRNA expression. Biochem Biophy. Res Comm. 1997;239:606–611.
Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance extrapolation of data to benzodiazepines and phenytom. J Pharmacokin Biopharm. 1980;8:165–176.
O’Sullivan TA, Bauer LA, Horn JR, et al. Disposition of drugs in cystic fibrosis. II. Hepatic blood flow. Clin Pharmacol Ther. 1991;50:450–455.
Author information
Authors and Affiliations
Corresponding author
Additional information
published June 22, 2000
Rights and permissions
About this article
Cite this article
Kulkarni, S.G., Pegram, A.A. & Smith, P.C. Disposition of acetaminophen and indocyanine green in cystic fibrosis-knockout mice. AAPS PharmSci 2, 18 (2000). https://doi.org/10.1208/ps020218
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/ps020218